PJ, October 2024, Vol 313, No 7990

UK to introduce framework for the manufacture of medicines at point of care

The government aims to relieve pressure on hospitals by delivering care in community settings and patients’ homes, expanding ‘hospital at home’ services.…

Medicines regulator receives 46 reports of hospitalisations linked to weight-loss drugs

As of 16 August 2024, the MHRA had received 5,073 reports of common gastrointestinal reactions related to GLP-1 RA use, of which 46 reported hospitalisation of the individual.…

Pharmacy access to GP records still in pilot phase, says NHS England

GP Connect will initially give pharmacists access to GP records, including medications, observations and investigations, with second-phase access to GP consultations and immunisations.…

PJ view: Community pharmacy is set up to fail when it comes to industrial action

As community pharmacists consider whether to engage in advisory industrial action, it is inevitable that patient safety will be affected one way or another, which the government needs to address.…

Test your knowledge of cardiovascular disease

This CPD and learning quiz can help you assess your knowledge of cardiovascular disease and related health issues.…

‘Rapid-dispersal’ naloxone wafers to be developed in £12m government scheme

Developed by King's College London, the wafers will disintegrate within seconds and can easily fit into a wallet.…

‘Every minute counts’: taking a national approach to time-critical medicines

Despite various initiatives to tackle the problem, safety incidents linked to the late administration of medicines, or medicines that have been omitted entirely, have remained stubbornly high for decades. A national focus may finally deliver a solution.…

NICE rejects second Alzheimer’s disease treatment for NHS use

Clinical trial evidence reveals that there are “significant health risks” linked to donanemab, with a third of patients experiencing amyloid-related imaging abnormalities as a result of brain swelling and bleeding.…

John Reid (1938–2024)

On 6 September 2024, John Reid MPharmS, aged 86 years, of Newark, Nottinghamshire. Mr Reid registered with the Society in 1959.…

Government-funded trial will test psilocybin as treatment for opioid use disorder

The project is one of four funded by the National Institute for Health and Care Research aimed at cutting harm from illegal drugs.…